Literature DB >> 30719118

miR-16 regulates proliferation and apoptosis of pituitary adenoma cells by inhibiting HMGA2.

Yingying Niu1, Hongbo Zhou2, Yancui Liu3, Yunfeng Wang4, Jinding Xie5, Chong Feng6, Ning An7.   

Abstract

Previous studies have revealed that elevated expression of high mobility group A2 (HMGA2) is closely associated with the occurrence of pituitary adenomas (PAs). The expression of microRNA (miR)-16 is deregulated in PA tissues. Bioinformatics analysis has demonstrated that there is a complementary region between seed region of miR-16 and 3'-untranslated region (3'-UTR) of HMGA2 gene. In the present study, it was investigated whether miR-16 may regulate the expression of HMGA2 and whether it is involved in the pathogenesis of PAs. A total of 52 patients with PAs were recruited. Normal brain tissues obtained from 12 patients with traumatic brain injury were used as controls. The association between miR-16 and HMGA2 was validated using dual-luciferase reporter gene assay. HP75 cells were cultured in vitro and divided into the following groups: miR control, miR-16 mimic, small interfering RNA (si)-negative control, si-HMGA2 and miR-16 mimic+si-HMGA2 groups. The expression of miR-16 and HMGA2 in HP75 cells was determined using qRT-PCR and western blot. Cell proliferation was detected using the Cell Counting Kit-8 assay and apoptosis was detected using the TdT-UTP nick end labeling assay. Compared with normal pituitary tissues, the expression of miR-16 in PA tissues was significantly decreased, while the mRNA and protein levels of HMGA2 were significantly increased. miR-16 targeted the 3'-UTR of HMGA2 gene and regulated the expression of HMGA2. Transfection with siRNAs targeting HMGA2 and/or miR-16 mimics inhibited the expression of HMGA2 and the proliferative ability of HP75 cells, whereas it increased apoptosis of HP75 cells. The downregulation of miR-16 and upregulation of HMGA2 were involved in the pathogenesis of PAs. Thus, it is hypothesized that miR-16 inhibited the proliferation and promoted apoptosis of HP75 cells by inhibiting HMGA2 expression.

Entities:  

Keywords:  apoptosis; high mobility group A2; microRNA-16; pituitary adenoma; proliferation

Year:  2018        PMID: 30719118      PMCID: PMC6350189          DOI: 10.3892/ol.2018.9872

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  26 in total

1.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

2.  miRDB: a microRNA target prediction and functional annotation database with a wiki interface.

Authors:  Xiaowei Wang
Journal:  RNA       Date:  2008-04-21       Impact factor: 4.942

Review 3.  Pituitary adenomas: results of 684 surgically treated patients and review of the literature.

Authors:  H H Oruçkaptan; O Senmevsim; O E Ozcan; T Ozgen
Journal:  Surg Neurol       Date:  2000-03

4.  HMGA2 induces pituitary tumorigenesis by enhancing E2F1 activity.

Authors:  Monica Fedele; Rosa Visone; Ivana De Martino; Giancarlo Troncone; Dario Palmieri; Sabrina Battista; Andrea Ciarmiello; Pierlorenzo Pallante; Claudio Arra; Rosa Marina Melillo; Kristian Helin; Carlo Maria Croce; Alfredo Fusco
Journal:  Cancer Cell       Date:  2006-06       Impact factor: 31.743

5.  miR-15a and miR-16-1 down-regulation in pituitary adenomas.

Authors:  Arianna Bottoni; Daniela Piccin; Federico Tagliati; Andrea Luchin; Maria Chiara Zatelli; Ettore C degli Uberti
Journal:  J Cell Physiol       Date:  2005-07       Impact factor: 6.384

6.  MicroRNAs differentially expressed in ACTH-secreting pituitary tumors.

Authors:  Fernando Colbari Amaral; Natalia Torres; Fabiano Saggioro; Luciano Neder; Hélio Rubens Machado; Wilson Araújo Silva; Ayrton Custódio Moreira; Margaret Castro
Journal:  J Clin Endocrinol Metab       Date:  2008-10-07       Impact factor: 5.958

7.  Overexpression of the HMGA2 gene in transgenic mice leads to the onset of pituitary adenomas.

Authors:  Monica Fedele; Sabrina Battista; Lawrence Kenyon; Gustavo Baldassarre; Vincenzo Fidanza; Andres J P Klein-Szanto; A F Parlow; Rosa Visone; Giovanna M Pierantoni; Eric Outwater; Massimo Santoro; Carlo M Croce; Alfredo Fusco
Journal:  Oncogene       Date:  2002-05-09       Impact factor: 9.867

8.  Prediction of mammalian microRNA targets.

Authors:  Benjamin P Lewis; I-hung Shih; Matthew W Jones-Rhoades; David P Bartel; Christopher B Burge
Journal:  Cell       Date:  2003-12-26       Impact factor: 41.582

9.  High mobility group A2 protein and its derivatives bind a specific region of the promoter of DNA repair gene ERCC1 and modulate its activity.

Authors:  Lars Borrmann; Ralf Schwanbeck; Tomasz Heyduk; Birte Seebeck; Piere Rogalla; Jörn Bullerdiek; Jacek R Wisniewski
Journal:  Nucleic Acids Res       Date:  2003-12-01       Impact factor: 16.971

10.  Human MicroRNA targets.

Authors:  Bino John; Anton J Enright; Alexei Aravin; Thomas Tuschl; Chris Sander; Debora S Marks
Journal:  PLoS Biol       Date:  2004-10-05       Impact factor: 8.029

View more
  4 in total

1.  Analysis of whole genome-wide microRNA transcriptome profiling in invasive pituitary adenomas and non-invasive pituitary adenomas.

Authors:  Chao Zhang; Yuan Qian; Yisheng Qiao; Yao Li; Wei Wang; Junjun Li; Xingli Deng
Journal:  Chin Neurosurg J       Date:  2019-12-02

2.  Prediction of clusters of miRNA binding sites in mRNA candidate genes of breast cancer subtypes.

Authors:  Dana Aisina; Anatoliy Ivashchenko; Raigul Niyazova; Shara Atambayeva
Journal:  PeerJ       Date:  2019-11-13       Impact factor: 2.984

3.  HMGA2 Promotes Brain Injury in Rats with Cerebral Infarction by Activating TLR4/NF-κB Signaling Pathway.

Authors:  Shaoyue Huang; Zhen Hong; Leguo Zhang; Jian Guo; Yanhua Li; Kuo Li
Journal:  Mediators Inflamm       Date:  2022-08-04       Impact factor: 4.529

Review 4.  Novel Insights into Pituitary Tumorigenesis: Genetic and Epigenetic Mechanisms.

Authors:  Vinaya Srirangam Nadhamuni; Márta Korbonits
Journal:  Endocr Rev       Date:  2020-12-01       Impact factor: 19.871

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.